Method for detecting pluripotent stem cells by detecting HES3

By using qPCR or digital PCR methods that combine HES3 gene and specific primer probes, the problems of long residual detection time and low sensitivity of pluripotent stem cells are solved, and rapid and accurate detection is achieved, ensuring the safety and clinicalness of cell products Application efficiency.

CN118910280APending Publication Date: 2024-11-08BEIJING ZEPHYRM BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411144654.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing pluripotent stem cell residue detection methods have problems such as long detection time, weak specificity and sensitivity, long cycle, and complex data analysis, which are difficult to meet the safety and efficiency requirements of clinical applications.

Method used

Using the HES3 gene as the detection target, combining specific primers and probes with qPCR or droplet digital PCR to achieve rapid, sensitive and accurate detection of pluripotent stem cell residues in human pluripotent stem cell products, reducing detection time and improving detection efficiency.

Benefits of technology

It realizes high sensitivity detection of pluripotent stem cells residues, ensures the safety of cell products, shortens detection time, improves detection efficiency, and reduces costs. It is suitable for the release of cell preparations and clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910280A_ABST
    Figure CN118910280A_ABST
Patent Text Reader

Abstract

The invention relates to a primer probe combination, a kit and a method for detecting HES3 gene expression, and application and a method of the primer probe combination for detecting pluripotent stem cells in a cell population. The primer probe combination comprises a primer pair and a probe, the primer pair comprises primer molecules with a nucleotide sequence as shown in SEQ ID NO: 2-3 or SEQ ID NO: 5-6, and the probe comprises a probe with a nucleotide sequence as shown in SEQ ID NO: 4 or SEQ ID NO: 7.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a method for detecting residual pluripotent stem cells in differentiated cells. Background Art

[0002] Pluripotent stem cells (PSC) include embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC). PSC has unlimited self-renewal and multidirectional differentiation potential, and has great application potential in the field of regenerative medicine. At present, with the rapid development of stem cell technology, more and more functional cell products derived from human pluripotent stem cells (hPSC) have been approved for clinical trials in various countries, but functional cell products derived from hPSC have a certain risk of tumorigenicity. On the one hand, if there are residual hPSC in the cell product, the residual hPSC may form teratomas in the body; on the other hand, there may be precursor cells with strong proliferation ability in the functional cell products induced by hPSC, which may proliferate in large quantities after being transplanted into the body to form tumors. Documents such as the "Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial)", "Technical Guidelines for Pharmaceutical Research and Evaluation of Human Stem Cell Products (Trial)", and "Technical Guidelines for Non-clinical Research of Human Stem Cell Products" issued by the China Food and Drug Administration all clearly point out that detection of residual pluripotent stem cells should be carried out.

[0003] The existing common methods for detecting residual pluripotent stem cells can be divided into two categories: direct detection and indirect detection. Direct detection refers to the detection target of pluripotent stem cells or tumors derived from them. Common methods include in vivo tumor formation and in vitro culture. Among them, the in vivo tumor formation method is closest to physiological conditions, but the detection cycle is long (at least 4 months) and the cost is high. In addition, the detection sensitivity is low and is closely related to the degree of immunodeficiency of the experimental animals used for detection, the injection site, and the amount of injected cells. The in vitro culture method generally refers to the use of hPSC culture conditions to culture the cells to be tested for 7 to 14 days. Undifferentiated hPSCs are cultured to form clones; this can be confirmed by detecting the expression of pluripotency-specific staining. The detection sensitivity of this method will be affected by the interaction between the test cells and pluripotent stem cells, and the detection cycle required is relatively long. Indirect detection refers to the detection target being a signal associated with pluripotent stem cells (such as the expression of marker genes). Commonly used indirect detection methods include dye-based quantitative PCR, real-time quantitative PCR (quantitative Polymerase Chain Reaction, qPCR) and digital PCR (digital Polymerase Chain Reaction, dPCR). The sensitivity and accuracy of such methods mainly depend on the choice of detection targets. PCR is a rapid detection method. With the continuous optimization of experimental conditions, there is the potential to develop cost-controlled, standardized operating procedures and highly sensitive detection methods.

[0004] The existing detection methods in the prior art have problems such as long culture time, weak specificity and sensitivity, long cycle, and complex data analysis. A new, simple and highly sensitive method and reagent for detecting residual pluripotent stem cells is needed in the art. Summary of the invention

[0005] The present invention provides a primer-probe combination and a detection method for detecting residual pluripotent stem cells in cell products derived from pluripotent stem cells using HES3 as a detection target. The specific primers and probes provided by the present invention are combined with qPCR or droplet digital PCR (ddPCR), and the minimum detection limit (sensitivity) reaches 0.0001%, which can quickly, sensitively and accurately detect residual pluripotent stem cells in human pluripotent stem cell products, ensure the safety of cell products, and shorten the detection time compared with conventional detection methods, and improve the detection efficiency and sensitivity.

[0006] In some aspects, the present invention provides use of the HES3 gene as a marker for detecting pluripotent stem cells in a sample.

[0007] In some aspects, the present invention provides a nucleic acid molecule for detecting the HES3 gene, comprising: a primer pair for amplifying all or part of the nucleic acid sequence of the HES3 gene, and a probe capable of specifically hybridizing to the sense strand or antisense strand of the nucleic acid sequence amplified by the primer pair.

[0008] In some embodiments, the primer pair is a forward primer having a nucleotide sequence shown as nnGCACGCATCAATGTGTCACT (SEQ ID NO: 13) and a reverse primer having a nucleotide sequence shown as nnCTCAACTCCAGGATGTCGGC (SEQ ID NO: 14), wherein n is A, T, C, G or none.

[0009] In some embodiments, the primer pair is a forward primer having a nucleotide sequence shown as nnGCAACTTCCGAAAGATTTC (SEQ ID NO: 16) and a reverse primer having a nucleotide sequence shown as nnAGGAGTTCTGAAGGCTTC (SEQ ID NO: 17), wherein n is A, T, C, G or none.

[0010] In some embodiments, the primer pair is a forward primer having a nucleotide sequence shown in SEQ ID NO: 2 and a reverse primer having a nucleotide sequence shown in SEQ ID NO: 3. In some embodiments, the primer pair is a forward primer having a nucleotide sequence shown in SEQ ID NO: 5 and a reverse primer having a nucleotide sequence shown in SEQ ID NO: 6.

[0011] In some embodiments, the probe has a nucleotide sequence as shown in nnACTACTCGCACCAGATCCGGAAGCGCAnn (SEQ ID NO: 15), wherein n is: A, T, C, G or nothing. In some embodiments, the probe has a nucleotide sequence as shown in nnACTTCACGCTCAACTCCAGGATnn (SEQ ID NO: 18), wherein n is: A, T, C, G or nothing. Preferably, the first nucleotide at the 5' end of the probe is not G.

[0012] In some embodiments, the probe is a probe having a nucleotide sequence as shown in SEQ ID NO: 4. In some embodiments, the probe is a probe having a nucleotide sequence as shown in SEQ ID NO:7.

[0013] In some embodiments, the nucleic acid molecule comprises: a forward primer having a nucleotide sequence as shown in SEQ ID NO:2, a reverse primer having a nucleotide sequence as shown in SEQ ID NO:3, and a probe having a nucleotide sequence as shown in SEQ ID NO:4.

[0014] In some embodiments, the nucleic acid molecule comprises: a forward primer having a nucleotide sequence as shown in SEQ ID NO:5, a reverse primer having a nucleotide sequence as shown in SEQ ID NO:6, and a probe having a nucleotide sequence as shown in SEQ ID NO:7.

[0015] In some embodiments, the probe is linked to a fluorescent reporter group at the 5' end and a fluorescent quencher group at the 3' end, or vice versa.

[0016] In some embodiments, the fluorescent reporter group is selected from Hydroxycoumarin, Methoxycoumarin, Alexa fluor, Aminocoumarin, Cy2, FAM, Alexa fluor 488, Fluorescein FITC, Alexafluor 430, JOE, TET, Alexa fluor 532, HEX, VIC, Cy3, TRITC, Alexa fluor 546, Alexafluor 555, R-phycoerythrin (PE), Rhodamine Red-X, TAMRA, Cy3.5, Rox, Alexa fluor568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Allophycocyanin, Alexafluor 633, Cy5, Alexa fluor 660, Cy5.5, TruRed, Alexa fluor 680 and Cy7.

[0017] In some embodiments, the fluorescent reporter group is selected from FAM, HEX, VIC, TAMRA, ROX, CY5, CY5.5, CY3, JOE, TET, Texas Red, NED and SYBR Green I. In some embodiments, the fluorescent quencher group is selected from Dabcyl, BHQ0, BHQ1, BHQ2, BHQ3, BBQ650, Eclipse and MGB.

[0018] In some embodiments, the nucleic acid molecule further comprises a nucleic acid molecule set for detecting an internal reference gene. In some embodiments, the internal reference gene is GAPDH, and the nucleic acid molecule set comprises a forward primer having a nucleotide sequence as shown in SEQ ID NO: 9, a reverse primer having a nucleotide sequence as shown in SEQ ID NO: 10, and a probe having a nucleotide sequence as shown in SEQ ID NO: 11.

[0019] In some aspects, the present invention provides a method for detecting and / or quantifying pluripotent stem cells in a sample, comprising detecting the expression of a HES3 gene in the sample, for example, by using a nucleic acid molecule disclosed herein for detecting a HES3 gene. In some embodiments, the sample is a differentiated cell population derived from pluripotent stem cells, such as human pluripotent stem cells.

[0020] In some embodiments, the method comprises extracting mRNA from the cell population and reverse transcribing it into cDNA.

[0021] In some embodiments, the detection of the expression of the HES3 gene is performed by polymerase chain reaction (PCR), for example, by real-time fluorescence quantitative PCR or digital PCR, and optionally, the reverse transcription and PCR are performed sequentially in separate reaction systems or in a one-step reaction system. The presence / amount of pluripotent stem cells in the sample can be determined by the CT value of PCR amplification. If the CT value is not measured or is higher than a certain threshold value, it can be determined that there is no pluripotent stem cell residue in the sample.

[0022] In some embodiments, the method further comprises detecting the expression of an internal reference gene in the cell population. In some embodiments, the internal reference gene is selected from genes encoding ATP5F1, TFRC, YWHAZ, RPLP0, RPLP1, ACTB, RPLP2, HPRT1, B2M, RPS18, TBP, PGK1, PPIA, GAPDH, and GUSB, preferably a gene encoding GAPDH.

[0023] In some embodiments, the pluripotent stem cells are selected from embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC). In some embodiments, the differentiated cells are selected from pluripotent stem cell-induced mesenchymal stem cells, pluripotent stem cell-induced dopaminergic neural precursor cells, and pluripotent stem cell-induced retinal pigment epithelial cells.

[0024] In some aspects, the present invention provides a kit comprising the nucleic acid molecule disclosed herein for detecting the HES3 gene. In some embodiments, the kit further comprises one or more of a nucleic acid extraction reagent, a PCR buffer, a DNA polymerase, a reverse transcriptase, and dNTPs.

[0025] In some aspects, the present invention relates to the use of a reagent for detecting the expression of the HES3 gene for detecting the presence of pluripotent stem cells in a sample and / or for quantifying the presence of pluripotent stem cells. In some embodiments, the sample is a differentiated cell population derived from pluripotent stem cells, such as human pluripotent stem cells. In some embodiments, the reagent comprises a nucleic acid molecule disclosed herein for detecting the HES3 gene. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the amplification curve of POU5F1 and HES3 gene expression in ESC-induced differentiated eMSC and ESC detected by RT-qPCR method.

[0027] Figure 2 The amplification curves of HES3 and GAPDH gene expression in dopaminergic neural progenitor cells (eDA), eMSC, retinal pigment epithelial cells (eRPE) and primary human foreskin fibroblasts (HFF-1) induced by iPSC, ESC, and hESC were detected by RT-qPCR.

[0028] Figure 3 This is the amplification curve of the expression of HES3 gene and GAPDH gene in eMSC, eMSC containing 0.0001% ESC, eMSC containing 0.0002% ESC, eMSC containing 0.001% ESC, eMSC containing 0.002% ESC, eMSC containing 0.01% ESC, eMSC containing 0.02% ESC, eMSC containing 0.1% ESC cell samples and ESC positive control detected by one-step qPCR.

[0029] Figure 4 This is the amplification curve of the expression of HES3 gene and GAPDH gene in eMSC, eMSC containing 0.0001% ESC, eMSC containing 0.0002% ESC, eMSC containing 0.001% ESC, eMSC containing 0.002% ESC, eMSC containing 0.01% ESC, eMSC containing 0.02% ESC, eMSC containing 0.1% ESC cell samples and ESC positive control detected by two-step qPCR.

[0030] Figure 5 The results of droplet amplification using digital PCR to detect the expression of HES3 and GAPDH genes in eMSCs, eMSC cell samples containing 0.001% ESCs, and ESC positive controls.

[0031] Figure 6 The figures are exemplary original images of amplified droplets for detecting the expression of HES3 gene and GAPDH gene in eMSC, eMSC cell sample containing 0.001% ESC and ESC positive control by digital PCR. Specific implementation plan

[0032] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. In addition, unless the context otherwise requires, terms in the singular should include plural forms, and terms in the plural should include singular forms. More specifically, as used in this specification and the appended claims, unless the context otherwise clearly indicates, the singular forms "one", "an" and "the / said" include plural referents. Unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "comprising" and other forms (such as "including" and "containing") is not restrictive.

[0033] As used herein, in relation to polymerase chain reaction, the term "primer pair" refers to a forward primer and a reverse primer. The terms "upstream primer" and "forward primer" used herein are used interchangeably and refer to an oligonucleotide sequence designed to be complementary to the sense strand (5' to 3' end direction) of a double-stranded target DNA sequence, thereby guiding the DNA polymerase to extend in the direction of the 3' to 5' end. The terms "downstream primer" and "reverse primer" used herein are used interchangeably and refer to an oligonucleotide sequence designed to be complementary to the antisense strand (3' to 5' end direction) of a double-stranded target DNA sequence, thereby guiding the DNA polymerase to extend in the direction of the 5' to 3' end.

[0034] As used herein, the term "human embryonic stem cell" refers to a stem cell separated or obtained from a human embryo within 14 days of fertilization without in vivo development, which can be self-renewed in vitro without restriction, and has the potential to differentiate into three germ layers. Human embryonic stem cells can come from the cell lines, preservation institutions or merchants publicly established in various documents to obtain the cell lines. The embryonic stem cells derived from the people used in the present invention can come from the embryonic stem cell lines established in the art, including but not limited to clinical-grade human embryonic stem cell lines (CTS-hES), MA01, MA09, ACT-4, H1, H7, H9, H14, WA25, WA26, WA27, Shef-1, Shef-2, Shef-3, Shef-4 and ACT30 embryonic stem cells. A lot of embryonic stem cell strains available for use have also been registered on the list (http: / / stemcells.nih.gov / registry / index.asp) of the National Institute of Health. Human embryonic stem cells can be purchased from, for example, Beijing Stem Cell Bank, Cellartis, ES Cell International, Wisconsin Alumni Research Foundation, and the like.

[0035] As used herein, the term "induced pluripotent stem cells" generally refers to a type of stem cell obtained by reprogramming adult cells, which has unlimited self-renewal ability and the potential to differentiate into cells of the three germ layers, and has pluripotency similar to that of embryonic stem cells.

[0036] Unless otherwise specified, the sequences described in the present invention are in the 5' to 3' direction.

[0037] Primers and probes targeting the gene sequence encoding HES3

[0038] The HES gene is a member of the basic-helix-loop-helix (bHLH) gene family. It is a negatively regulated bHLH transcription factor that participates in regulating stem cell proliferation and differentiation. Among them, the HES3 (Hes family BHLH transcription factor 3) gene is a target gene of the embryonic stem cell-specific transcription factor network, and its expression is limited to undifferentiated pluripotent stem cells. The inventors of the present application unexpectedly found that, unlike genes such as POU5F1, SOX2, ESRG, LIN28A, NANOG, and TDGF1, which are expressed not only in pluripotent stem cells but also in differentiated cells, the HES3 gene is more suitable as a marker for detecting pluripotent stem cells. For example, SOX2 is a common hPSC-specific gene, but it is also expressed in neural stem cells, so SOX2 is not suitable for detecting the residues of hPSC in induced neural stem cells or neural precursor cells; LIN28A is expressed in induced liver cells, endothelial cells, and pancreatic islet bodies, so LIN28A is not suitable for detecting hPSC residues in these functional cells. The inventors of the present application have found that the HES3 gene is specifically expressed in pluripotent stem cells, and its expression is almost undetectable or negative in various differentiated cells.

[0039] In some aspects, the present invention provides a primer-probe combination, comprising a primer pair for amplifying a nucleic acid fragment encoding a sequence of HES3, and a probe capable of specifically hybridizing to a sense strand or an antisense strand of the nucleic acid fragment amplified by the primer pair, wherein the primer pair comprises a forward primer and a reverse primer.

[0040] Primer pairs and probe sequences can be designed based on the DNA sequence or mRNA sequence encoding HES3. Preferably, the mRNA sequence comprising the sequence shown in SEQ ID NO: 1 is used as a template to design primer pairs and probes for the gene sequence encoding HES3. In one embodiment, primers and probes can be designed using the Primer-Blast program of NCBI (https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / index.cgi?LINK_LOC=BlastHome).

[0041] The primer pair and the probe can be completely matched with the target sequence to be detected. However, based on the working principle of the primer and the probe, as long as the specificity, sensitivity and recovery rate of the detection are not impaired, the primer and the probe can have a single or continuous mismatch of several nucleotides with the target sequence to be detected. For example, the primer (whether forward primer or reverse primer) can contain a mismatch of 1-2 nucleotides at the 5' end, and the probe can contain a mismatch of 1-2 nucleotides at the 5' and / or 3' ends.

[0042] Specifically, the primer pair for amplifying the nucleic acid sequence encoding HES3 can be selected from the following combinations:

[0043] a) a forward primer having a sequence as shown in SEQ ID NO: 2 or 13, or a sequence having at least 90% identity to the sequence as shown in SEQ ID NO: 2, and a reverse primer having a sequence as shown in SEQ ID NO: 3 or 14, or a sequence having at least 90% identity to the sequence as shown in SEQ ID NO: 3; and

[0044] b) a forward primer having a sequence as shown in SEQ ID NO:5 or 16, or a sequence having at least 90% identity to the sequence as shown in SEQ ID NO:5, and a reverse primer having a sequence as shown in SEQ ID NO:6 or 17, or a sequence having at least 90% identity to the sequence as shown in SEQ ID NO:6.

[0045] Specifically, the probe capable of specifically hybridizing with the sense strand or antisense strand of the nucleic acid sequence amplified by the primer pair can be selected from:

[0046] a) a probe having a sequence as shown in SEQ ID NO: 4 or 15, or a sequence having at least 80% identity to the sequence as shown in SEQ ID NO: 4; and

[0047] b) a probe having a sequence as shown in SEQ ID NO: 7 or 18, or a sequence having at least 80% identity to the sequence as shown in SEQ ID NO: 7.

[0048] Cell products derived from pluripotent stem cells

[0049] Stem cells are a type of cell with self-replication and multidirectional differentiation potential. Among them, pluripotent stem cells have the ability to differentiate into almost all cell types. The pluripotent stem cells of the present invention include embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC). The technology of inducing pluripotent stem cells to derive a variety of specific differentiated cells is well known in the art or routinely used. The differentiated cell types include, but are not limited to, for example, hematopoietic stem cells, and the various types of blood cells they produce, including erythrocytes, B lymphocytes, T lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, monocytes, macrophages, and platelets; neural stem cells in the brain, and the nerve cells (neurons) and two major types of non-neural cells (astrocytes and oligodendrocytes) they produce; epithelial stem cells in the lining of the digestive tract, which produce absorptive cells, goblet cells, Paneth cells, and enteroendocrine cells; skin stem cells; mesenchymal stem cells, and the osteoblasts, chondrocytes, adipocytes, and other types of connective tissue cells differentiated therefrom, and the like.

[0050] In recent years, the research and development and clinical transformation of stem cell drugs have continuously achieved breakthrough progress. The stem cell products currently being studied clinically include cell products derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC), as well as adult stem cell products with tissue-specific differentiation ability, of which hESC and hiPSC are both human pluripotent stem cells (hPSC) products. As used herein, "cell products derived from pluripotent stem cells" refer to cell products obtained by directing pluripotent stem cells to differentiate into specific cell types through a series of methods and means, and the cell products include, for example, mesenchymal stem cells, dopaminergic neural precursor cells, retinal pigment epithelial cells, etc. The technology of inducing pluripotent stem cells to derive various functional cells is well known to ordinary technicians in the field. ESC / iPSC-derived cell therapy products may cause the risk of teratomas, other wrong-mode tumors or precancerous lesions due to a small amount of residual pluripotent stem cells and continuously proliferating differentiated daughter cells. Therefore, in order to effectively control this risk, a sensitive detection method for detecting undifferentiated pluripotent stem cell contamination in the final product is required.

[0051] In some aspects, the present invention provides a method for detecting pluripotent stem cells in a cell population, the method comprising: using the primer-probe combination disclosed herein to detect the expression of a gene encoding HES3 in the cell population. Preferably, the cell population is a cell product derived from pluripotent stem cells, such as mesenchymal stem cells, dopaminergic neural precursor cells, and retinal pigment epithelial cells derived from pluripotent stem cells.

[0052] Method for detecting HES3 gene expression

[0053] Preferably, the detection of the gene expression encoding HES3 is performed by polymerase chain reaction (PCR), for example, by real-time fluorescence quantitative PCR or digital PCR. The common advantages of these two methods are short detection cycle, high sensitivity, easy standardization of operation steps, and the qPCR method has the advantages of low cost and more universality than the dPCR method. After selecting a suitable detection target gene, optimizing probes, primers and amplification procedures, and passing a series of standardized verifications, a high-sensitivity, high-accuracy and low-cost rapid stem cell residue detection method can be established for the release of cell preparations to improve the safety of clinical applications. The method disclosed herein may further include detecting the expression of an internal reference gene in the cell population, wherein the internal reference gene is selected from the group consisting of genes encoding ATP5F1, TFRC, YWHAZ, RPLP0, RPLP1, ACTB, RPLP2, HPRT1, B2M, RPS18, TBP, PGK1, PPIA, GAPDH and GUSB, preferably a gene encoding GAPDH, wherein the detection of the expression of the internal reference gene is performed by using an internal reference gene primer pair and an internal reference gene probe, the internal reference gene primer pair being used to amplify a nucleic acid sequence encoding the internal reference gene, and the internal reference gene probe being capable of specifically hybridizing to a nucleic acid sequence amplified by the internal reference gene primer pair.

[0054] For the detection of the expression of the internal reference gene in the cell population, those skilled in the art can select commercially available primer pairs and probes for the internal reference gene as needed, or design primer pairs and probe sequences based on the sequence of the internal reference gene. The method of designing primers and probes based on specific sequences is well known to those skilled in the art. For example, the primer pairs and probes for the internal reference gene can be primer pairs and probe sequences designed based on the mRNA sequence containing the sequence shown in SEQ ID NO:8.

[0055] In a preferred embodiment, the internal reference gene is a gene encoding GAPDH, the internal reference gene primer pair is a forward primer having a sequence as shown in SEQ ID NO:9, and a reverse primer having a sequence as shown in SEQ ID NO:10; the internal reference gene probe is a probe having a sequence as shown in SEQ ID NO:11.

[0056] Optionally, the probe disclosed herein has a 5'-end fluorescent reporter group modification and a 3'-end fluorescent quencher group modification, or the probe has a 5'-end fluorescent quencher group modification and a 3'-end fluorescent reporter group modification. Examples of the fluorescent reporter group include, but are not limited to, Alexa Fluor 350, Alexa Fluor 405, Pacific Blue, DAPI, AMCA, Cascade Blue, EviTagTM Quantum Dots-Lake Placid Blue, Fluoroblue, Image-Blue, Marina Blue, Cy2, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 488 fluorescent nanogold, Alexa Fluor 500, Alexa Fluor 514, fluorescein isothiocyanate (FITC), fluorescein, HNP, 5-FAM, 6-FAM, BODIPY FL, CMNB-caged fluorescein, Cyanine 2, DTAF, DTAF / FITC, dUTP-biotin and avidin FITC, dUTP-FITC, EviTagTM quantum dots-Adirondack Green, EviTagTM quantum dots-Catskill Green, fluorescein-5-EX succinimidyl ester, HiFITC, JOE, MFP488, Oregon Green 488, Oregon Green 514, Qdot 525, TET, CAL Gold 540, NL493, GFP, Cy3, Cy3B, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, R-phycoerythrin, B-phycoerythrin, HNP / Fast Red TR, 5-TAMRA, Atto 550, CAL Orange 560, Cyanine 3, DyLight 547, EviTagTM quantum dots-Birch yellow, EviTagTM quantum dots-Hops yellow, HEX (hexachloro-6-methylfluorescein), NED, Qdot565, 570, TRITC, VIC, NL557, Cy3.5, Alexa Fluor 568, ROX, DyeMer 488 / 605, DyeMer 488 / 615, CAL Red 590, CAL Red 610, Cyanine 3.5, DyeMer 488 / 605, DyeMer 488 / 615, EviTagTM quantum dots-Fort Orange, Lissamine Rhodamine, MFP555, Qdot 585, Qdot 605, ROX, R-phycoerythrin-Texas Red, Rhodamine Red-X, TMR Red, Cy5, Cy5.5, CypHer5E, Alexa Fluor594, Alexa Fluor 594 fluorescent nanogold, Alexa Fluor 610, Alexa Fluor 610–R-PE, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor647–R-phycoerythrin, Alexa Fluor 660, Texas Red, DyeMer 488 / 630, Allophycocyanin, PI, Allophycocyanin-cyanin 5, Allophycocyanin-cyanin 5.5, Atto 647, CAL Red 635, Cyanine 5, DyLight 647, DyeMer 488 / 630, Dyomics647, Lightcycler Red-640, PBXL-1, PBXL-3, Perichlorophyll (PerCP), PerCP-Cy5.5, Qdot655, Quantum Red, Examples of the fluorescence quenching group include, but are not limited to, Alexa Fluor 488*, Alexa Fluor 532*, Alexa Fluor 546*, Alexa Fluor 555*, Alexa Fluor 594*, Alexa Fluor 647*, Alexa Fluor 660*, Alexa Fluor 750*, AMCA, amino linkers BHQ1, BHQ2, biotin, CY-3, CY-5, DABCYL, digoxin, 530 / 550*, 493 / 503*, 558 / 569*, 564 / 570*, 576 / 589*, 581 / 591*, 630 / 650-X*, Eclipse, FAM, FITC, HEX, JOE, Phosphate, ROX, Rhodamine Green, Rhodamine Red, TAMRA, TET, Texas Red-X, Thiol-C6 SS.

[0057] In some embodiments, the fluorescent reporter group at the 5' end is selected from Hydroxycoumarin, Methoxycoumarin, Alexa fluor, Aminocoumarin, Cy2, FAM, Alexa fluor 488, FluoresceinFITC, Alexa fluor 430, JOE, TET, Alexa fluor 532, HEX, VIC, Cy3, TRITC, Alexa fluor546, Alexa fluor 555, R-phycoerythrin (PE), Rhodamine Red-X, TAMRA, Cy3.5, Rox, Alexafluor 568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Allophycocyanin, Alexa fluor 633, Cy5, Alexa fluor 660, Cy5.5, TruRed, Alexa fluor 680 and Cy7.

[0058] In some embodiments, the fluorescence quencher group at the 3' end is selected from Dabcyl, BHQ0, BHQ1, BHQ2, BHQ3, Eclipse and MGB.

[0059] In some embodiments, the 5' end of the probe is modified with a reporter group selected from FAM (6-carboxyfluorescein), HEX (hexachloro-6-methylfluorescein), VIC (green fluorescent protein), TAMRA (carboxytetramethylrhodamine), ROX (6-carboxyrhodamine) and CY5 (cyanine dye), and the 3' end is modified with a fluorescence quenching group selected from Dabcyl (4 (4' dimethylaminophenylazo) benzoic acid), BHQ1 (black hole quencher 1) and BHQ2 (black hole quencher 2).

[0060] In some embodiments, pluripotent stem cells are detected by real-time fluorescence quantitative PCR using total RNA extracted from the cell population to be tested as a template, or optionally using cDNA obtained by reverse transcription of the total RNA as a template, and the presence of pluripotent stem cells in the cell population is detected by detecting the amplification signal.

[0061] In some embodiments, pluripotent stem cells are detected by digital PCR using total RNA extracted from the cell population to be tested as a template, or optionally using cDNA obtained by reverse transcription of the total RNA as a template, and the presence of pluripotent stem cells in the cell population is detected by detecting the amplified copy number.

[0062] In some embodiments, the method uses RNA as a template for one-step qPCR detection, comprising the following steps:

[0063] a) extracting total RNA from the cell product;

[0064] b) using RNA as a template and the primer-probe combination described in the present invention to amplify by real-time fluorescence quantitative PCR to obtain an amplified product, and detecting the expression level of the HES3 gene in the amplified product. The level of HES3 gene expression indicates the level of residual pluripotent stem cells in the cell product.

[0065] In the method, preferably, the one-step qPCR reaction conditions are: reverse transcription at 55°C for 15 min; pre-denaturation at 95°C for 30 s, denaturation temperature of each cycle at 95°C for 10 s, annealing extension temperature at 60°C for 30 s, and amplification reaction cycle number of 45-50.

[0066] In some embodiments, the method uses cDNA as a template for two-step qPCR detection, comprising the following steps:

[0067] a) extracting total RNA of the cell product and reverse transcribing it into cDNA;

[0068] b) using cDNA as a template and the primer-probe combination described in the present invention to amplify by real-time fluorescence quantitative PCR to obtain an amplified product, and detecting the expression level of the HES3 gene in the amplified product. The level of HES3 gene expression indicates the level of residual pluripotent stem cells in the cell product.

[0069] In the method, preferably, the RT-qPCR uses a 2×qPCR Mix premixed reaction solution, and the RT-qPCR reaction conditions are: pre-denaturation temperature 95°C, pre-denaturation time 5min, each cycle denaturation temperature 95°C, denaturation time 10s, annealing extension temperature 60°C, annealing extension time 30s, and amplification reaction cycle number 45-50. In some embodiments, the concentration ratio of the upstream primer, the downstream primer, and the probe in the qPCR reaction system is 4:4:2.

[0070] In some embodiments, the method uses RNA as a template for one-step ddPCR detection, comprising the following steps:

[0071] a) extracting total RNA from the cell product;

[0072] b) using RNA as a template and the primer-probe combination described in the present invention to amplify by real-time fluorescence quantitative PCR to obtain an amplified product, and detecting the expression level of the HES3 gene in the amplified product. The level of HES3 gene expression indicates the level of residual pluripotent stem cells in the cell product.

[0073] In the method, preferably, the one-step ddPCR reaction conditions are: reverse transcription at 55°C for 15 min; pre-denaturation at 95°C for 30 s, denaturation temperature of each cycle at 95°C for 10 s, annealing extension temperature at 60°C for 30 s, and amplification reaction cycle number of 45-50.

[0074] In some embodiments, the method uses cDNA as a template to perform two-step ddPCR detection, comprising the following steps:

[0075] a) extracting total RNA of the cell product and reverse transcribing it into cDNA;

[0076] b) using cDNA as a template and the primer-probe combination described in the present invention to amplify by real-time fluorescence quantitative PCR to obtain an amplified product, and detecting the expression level of the HES3 gene in the amplified product. The level of HES3 gene expression indicates the level of residual pluripotent stem cells in the cell product.

[0077] In the method, preferably, the ddPCR uses a ddPCR Mix premixed reaction solution, and the ddPCR reaction conditions are: pre-denaturation temperature 95°C, pre-denaturation time 3min, denaturation temperature 95°C for each cycle, denaturation time 30s, annealing extension temperature 60°C, annealing extension time 30s, and amplification reaction cycle number 45-50. In some embodiments, the concentration ratio of the upstream primer, the downstream primer, and the probe in the ddPCR reaction system is 4:4:1.

[0078] Reagent test kit

[0079] In some aspects, the present invention provides a kit for detecting pluripotent stem cells in a cell population, comprising a primer-probe combination disclosed herein, and optionally a primer pair and a probe for detecting the expression of an internal reference gene, such as a primer pair and a probe for detecting the expression of GAPDH disclosed herein. The kit of the present invention may further comprise one or more of a nucleic acid extraction reagent, a PCR buffer, a DNA polymerase, a reverse transcriptase, and dNTPs.

[0080] For detecting pluripotent stem cells in a cell population using the kit of the present invention, RNA in the cell population can be extracted, and PCR can be performed on the RNA using the aforementioned primer-probe combination. Methods for extracting RNA from a cell population are well known in the art, and can be used, for example, for extraction, or for extraction using a commercially available RNA extraction reagent. Optionally, the extracted RNA can also be reverse transcribed into cDNA. Methods for reverse transcribing RNA into cDNA are well known in the art.

[0081] In the pluripotent stem cell detection using the kit of the present invention, for example, FastStart Taq DNA polymerase (Roche), Ex Taq (registered trademark, Takara), Z-Taq, AccuPrime Taq DNA polymerase, polymerase contained in M-PCR kit (QIAGEN), hot start Taq DNA polymerase (Vazyme), AceTaq DNA polymerase (Vazyme), etc. can be used as the DNA polymerase as described above. The method of selecting suitable PCR reaction conditions based on primers is well known in the art, and those of ordinary skill in the art can select the best conditions according to primer length, GC content, target specificity and sensitivity, properties of the polymerase used, etc.

[0082] Beneficial Effects of the Invention

[0083] Although a large number of genes that can be specifically expressed in pluripotent stem cells have been reported in the prior art, these genes are also expressed in functional cells or primary cells differentiated from pluripotent stem cells, and cannot solve the problem of universality in the large-scale production of detection of hPSC residues in hPSC-derived functional cells. The HES3 provided by the present invention is almost not expressed in cells differentiated from hPSC or primary cells, and can be used for detection of cell products obtained by differentiation of hPSC (a series of cells such as mesenchymal stem cells, neural cells, retinal pigment epithelial cells, etc.) without replacing marker genes; and the RT-qPCR detection technology has the characteristics of accurate and stable detection, and the minimum detection limit (sensitivity) of HES3 can reach 0.0001%. Compared with the single-cell transcriptome sequencing method, it has considerable detection sensitivity and greatly reduces the detection cost, and is more suitable for routine detection and batch release in the production process of cell preparations; compared with the longer detection time (10-14 days) of the culture method, the detection method provided in the present invention only takes 2-4 hours to complete the entire operation, greatly shortening the detection time, improving the detection efficiency, and avoiding the false negative effect caused by long-term co-culture, with higher specificity and higher detection sensitivity; and can better ensure the clinical application safety of functional cell products.

[0084] The present invention will be further explained below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0085] Example

[0086] Description of the sources of reagents and raw materials in the following examples:

[0087] RNA extraction kit was purchased from Vazyme Biotechnology Co., Ltd. RNA reverse transcription kit was purchased from Thermo Fisher Scientific (Invitrogen)\ Kangwei Century Biotechnology Co., Ltd. qPCR kit was purchased from Vazyme (Nuoweizan). ddPCR Mix was purchased from ApBiotech Co., Ltd.

[0088] Human embryonic stem cells (ESC-1 and ESC-2) were derived from the human embryonic stem cell working bank of Beijing Zehui Chenxing Biotechnology Co., Ltd. Human induced pluripotent stem cells (iPSC) were derived from an established iPSC cell bank. Mesenchymal stem cells (eMSC), dopaminergic neural precursor cells (eDA), and retinal pigment epithelial cells (eRPE) were obtained by directed differentiation of human embryonic stem cells. Primary human foreskin fibroblasts (HFF-1) were purchased from ATCC.

[0089] Example 1: Detection of the expression of candidate pluripotency genes POU5F1 and HES3 in human embryonic stem cells (ESC) and mesenchymal stem cells (eMSC) obtained by induced differentiation of human embryonic stem cells

[0090] First, total mRNA was extracted from ESC and eMSC samples using an RNA extraction kit (FastPure Cell / Tissue Total RNA Isolation Kit, #RC101, Vazyme). According to the amount of 1 μg RNA, the total mRNA was extracted using a reverse transcription kit (SuperScript TM IV First-Strand Synthesis System, 18091200, Invitrogen) was used to reverse transcribe mRNA into cDNA, and the obtained cDNA was diluted 10 times with DEPC water. The relative expression of POU5F1 and HES3 genes in ESCs and eMSCs was detected using a qPCR kit (AceQ U+Probe Master Mix, Q113, Vazyme). The reaction system is shown in Table 1, and the reaction procedure is shown in Table 2.

[0091] Table 1 Reaction system

[0092]

[0093] Table 2 Reaction procedure

[0094]

[0095] Primers and probes were designed using the mRNA sequences of candidate pluripotency genes POU5F1 (SEQ ID NO: 12), HES3 (SEQ ID NO: 1) and internal reference gene GAPDH (SEQ ID NO: 8) as templates, respectively (Table 3).

[0096] Table 3 Primer probe sequences

[0097]

[0098]

[0099] The upstream primer, downstream primer and probe sequences of gene POU5F1 are shown as SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively.

[0100] Each assay was performed in duplicate. Figure 1 The CT values ​​are shown in Table 4. NTC is the blank control.

[0101] Table 4 Amplified CT values

[0102]

[0103] Not detected means that no expression was detected. The higher the CT value, the lower the background expression. It can be seen from the qPCR test results that HES3 is positively expressed in ESC, and no effective amplification is detected in differentiated eMSC. Although POU5F1 is highly expressed in ESC, it still has low expression in differentiated eMSC. When the cDNA template is diluted 10 times, obvious positive amplification can still be detected. There are also literature reports that POU5F1 is positively expressed in umbilical cord blood-derived MSC. Therefore, compared with the commonly used pluripotency target gene POU5F1 in this field, HES3 is more suitable for residual PSC detection in MSCs obtained by differentiation of pluripotent stem cells.

[0104] Example 2: Detection of the expression level of HES3 in different pluripotent stem cells (ESC-1, ESC-2, IPSC) and differentiated cells (hESC-differentiated dopaminergic neural precursor cells (eDA), mesenchymal stem cells (eMSC), retinal pigment epithelial cells (eRPE) and primary human foreskin fibroblasts HFF-1)

[0105] First, the total mRNA of the above cell samples was extracted using an RNA extraction kit (FastPure Cell / Tissue Total RNA Isolation Kit, #RC101, Vazyme); according to the amount of 1 μg RNA, the reverse transcription kit (SuperScript TM The RNA was reverse transcribed into cDNA using IV first-strand synthesis system, 18091200, Invitrogen), and the obtained cDNA was diluted 10 times with DEPC water. Finally, the expression of HES3 and GAPDH genes in the above cells was detected by RT-qPCR detection method according to the qPCR kit (AceQ U+Probe Master Mix, Q113, Vazyme). The reaction system is shown in Table 5, the reaction procedure is shown in Table 6, and the probe primer sequence is shown in Table 7.

[0106] Table 5 Reaction system

[0107]

[0108] Table 6 Reaction procedure

[0109]

[0110] Table 7 Detection primer and probe sequences

[0111]

[0112] Each assay was performed in duplicate. Figure 2 The CT values ​​are shown in Table 8.

[0113] Table 8 Amplified CT values

[0114]

[0115]

[0116] The results of qPCR detection showed that HES3 was positively expressed in two ESC cells and one iPSC cell, no effective amplification was detected in the two eMSC cells after differentiation, and the expression was negative. The expression level in dopaminergic neural precursor cells (DA), retinal pigment epithelial cells (RPE) and human foreskin fibroblasts (HFF-1) was extremely low (CT value greater than 35).

[0117] Example 3: One-step qPCR detection of HESC gene minimum detection limit using RNA as template

[0118] Charge 2×10 68 tubes of eMSC cells were prepared, of which 7 tubes of eMSC were mixed with ESC according to different cell number ratios to prepare the following cell samples: eMSC containing 0.0001% ESC; eMSC containing 0.0002% ESC; eMSC containing 0.001% ESC; eMSC containing 0.002% ESC; eMSC containing 0.01% ESC; eMSC containing 0.02% ESC; eMSC containing 0.1% ESC, and another tube of ESC cells was taken as a positive control, and the cell samples were prepared with reference to Table 9. Total RNA was extracted from the above cell samples using an RNA extraction kit (FastPure Cell / Tissue Total RNA Isolation Kit, #RC101, Vazyme); the extracted RNA concentration is shown in Table 10. The extracted RNA was directly used as a template without dilution. Finally, the expression of HES3 and GAPDH genes in the above cells was detected using a one-step qPCR kit (HiScript II U+One Step qRT-PCR Probe Kit, Q222-CN-00, Vazyme). The negative amplification control used DEPC water as a template. The reaction system is shown in Table 11, the reaction procedure is shown in Table 12, and the detection probe primer sequence is shown in Table 13.

[0119] Table 9 Cell sample preparation

[0120]

[0121]

[0122] Table 10 RNA extraction concentration

[0123]

[0124]

[0125] Table 11 Reaction system

[0126]

[0127] Table 12 Reaction procedure

[0128]

[0129] Table 13. Primer and probe sequences for detection.

[0130]

[0131]

[0132] Each assay was performed in duplicate. Figure 3The CT values ​​are shown in Table 14.

[0133] Table 14 Amplified CT values

[0134]

[0135]

[0136] The qPCR test results show that HES3 was not effectively amplified in the negative amplification control and eMSC, and positive amplification was detected in the eMSC containing 0.0001% ESC, eMSC containing 0.0002% ESC, eMSC containing 0.001% ESC, eMSC containing 0.002% ESC, eMSC containing 0.01% ESC, eMSC containing 0.02% ESC, eMSC containing 0.1% ESC, and the positive control ESC cells. Starting from 0.002% reference, the amplification CT value is linearly related to the ESC spike amount. The experimental results show that the quantitative limit of this method can reach 0.002% in mesenchymal stem cells (eMSC cells) obtained by induced differentiation of human embryonic stem cells, and the minimum detection limit can reach 0.0001%.

[0137] Example 4: Two-step qPCR detection of HESC gene minimum detection limit using cDNA as template

[0138] Charge 2×10 6 8 tubes of eMSC cells were prepared, of which 7 tubes of eMSC were mixed according to different cell number ratios to prepare the following cell samples: eMSC containing 0.0001% ESC; eMSC containing 0.0002% ESC; eMSC containing 0.001% ESC; eMSC containing 0.002% ESC; eMSC containing 0.01% ESC; eMSC containing 0.02% ESC; eMSC containing 0.1% ESC, and another tube of ESC cells was taken as a positive control, and cell samples were prepared with reference to Table 9. Total RNA was extracted from the above cell samples using an RNA extraction kit (FastPureCell / Tissue Total RNA Isolation Kit, #RC101, Vazyme); 1 μg RNA was extracted using a reverse transcription kit (SuperScript TMIV First-Strand Synthesis System, 18091200, Invitrogen) was used to reverse transcribe RNA into cDNA, and the obtained cDNA was used directly as a template without dilution. The expression of HES3 and GAPDH genes in the above cells was detected by RT-qPCR detection method using a qPCR kit (AceQ U+Probe Master Mix, Q113, Vazyme). The reaction system is shown in Table 15, the reaction procedure is shown in Table 16, and the probe primer sequences are shown in Table 13.

[0139] Table 15 Reaction system

[0140]

[0141] Table 16 Reaction procedure

[0142]

[0143] Each assay was performed in duplicate. Figure 4 The CT values ​​are shown in Table 17.

[0144] Table 17 Amplification CT values

[0145]

[0146]

[0147] The qPCR test results show that HES3 was not effectively amplified in the negative amplification control eMSC and eMSC containing 0.0002% ESC, and could be detected in a single well in two duplicate wells of the eMSC sample containing 0.0001% ESC; positive amplification could be detected in the eMSC containing 0.001% ESC, eMSC containing 0.002% ESC, eMSC containing 0.01% ESC, eMSC containing 0.02% ESC, eMSC containing 0.1% ESC, and the positive control ESC cells, and the amplification CT value was linearly related to the ESC spike amount starting from 0.01% reference. The experimental results show that the quantitative limit of this method can reach 0.01% in mesenchymal stem cells (eMSC cells) obtained by induction differentiation of human embryonic stem cells, and the minimum detection limit can reach 0.001%.

[0148] Example 5: Minimum detection limit of HESC gene by two-step digital PCR using cDNA as template

[0149] Charge 2×10 62 tubes of eMSC cells were prepared, of which 1 tube of eMSC was mixed with ESC to prepare an eMSC cell sample containing 0.001% ESC, and another tube of ESC cells was taken as a positive control, and the cell sample was prepared with reference to Table 18. The total RNA of the above cell samples was extracted using an RNA extraction kit (FastPure Cell / Tissue Total RNA Isolation Kit, #RC101, Vazyme); according to the amount of 1 μg RNA, the RNA was reverse transcribed into cDNA using a reverse transcription kit (HiFiScript gDNA Removal RTMasterMix, CW2020M, Kangwei Century), and the obtained cDNA was diluted or not diluted according to Table 19, and after treatment, it was used as a template, and the expression of HES3 and GAPDH genes in the above cells was detected by digital PCR detection method using ddPCR Mix (Aipbai Biotechnology Co., Ltd., ruby ​​digital PCR amplification system), the reaction system is shown in Table 20, the reaction procedure is shown in Table 21, and the probe primer sequence is the same as Table 7.

[0150] Table 18 Cell sample preparation

[0151]

[0152]

[0153] Table 19 cDNA template dilution

[0154]

[0155] Table 20 Reaction system

[0156]

[0157]

[0158] Table 21 Reaction procedure

[0159]

[0160] The results of amplification droplets are as follows Figure 5 , 6 As shown, the positive droplets and gene copy number values ​​are shown in Table 22.

[0161] Table 22 Positive droplets and gene copy data

[0162]

[0163] The results of digital PCR showed that the GAPDH gene was positively amplified in each sample, and the copy number in eMSC and eMSC samples containing 0.001% ESC was close to 1:1, which further proved that the template loading amount of the two samples was consistent. ESC is a completely different cell type, and the copy ratio of GAPDH in ESC and eMSC samples is between 1:2 and 1:3, indicating that GAPDH is higher in eMSC than in ESC, but the effect on quantitative calculation is relatively weak.

[0164] After retrospective confirmation of the original droplet photos, no positive amplification of the target gene HES3 was detected in eMSC. Positive amplification droplets could be detected in both the positive control ESC cells and the reference sample eMSC containing 0.001% ESC. The experimental results showed that the minimum detection limit of this method in mesenchymal stem cells (eMSC cells) obtained by induced differentiation of human embryonic stem cells can reach 0.001%.

Claims

1. A nucleic acid molecule for detecting a HES3 gene, comprising: A primer pair for amplifying all or part of the nucleic acid sequence of the HES3 gene, and A probe that can specifically hybridize to the sense strand or antisense strand of the nucleic acid sequence amplified by the primer pair.

2. The nucleic acid molecule according to claim 1, wherein the primer pair is selected from the following combination: a) a forward primer having the nucleotide sequence shown in SEQ ID NO: 13, and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 14; and b) a forward primer having the nucleotide sequence shown in SEQ ID NO:16, and a reverse primer having the nucleotide sequence shown in SEQ ID NO:

17.

3. The nucleic acid molecule according to claim 2, wherein the primer pair is selected from the following combination: a) a forward primer having the nucleotide sequence shown in SEQ ID NO: 2, and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 3; and b) a forward primer having the nucleotide sequence shown in SEQ ID NO: 5, and a reverse primer having the nucleotide sequence shown in SEQ ID NO:

6.

4. The nucleic acid molecule according to any one of claims 1 to 3, wherein the probe is selected from: a) a probe having a nucleotide sequence as shown in SEQ ID NO: 15; and b) A probe having the nucleotide sequence shown in SEQ ID NO:

18.

5. The nucleic acid molecule according to claim 4, wherein the probe is selected from: a) a probe having a nucleotide sequence as shown in SEQ ID NO: 4; and b) A probe having a nucleotide sequence as shown in SEQ ID NO:

7.

6. The nucleic acid molecule according to claim 5, which is selected from the following combination: a) a forward primer having a nucleotide sequence as shown in SEQ ID NO: 2, a reverse primer having a nucleotide sequence as shown in SEQ ID NO: 3, and a probe having a nucleotide sequence as shown in SEQ ID NO: 4; and b) a forward primer having a nucleotide sequence as shown in SEQ ID NO:5, a reverse primer having a nucleotide sequence as shown in SEQ ID NO:6, and a probe having a nucleotide sequence as shown in SEQ ID NO:

7.

7. The nucleic acid molecule according to any one of claims 1 to 6, wherein the probe is connected to a fluorescent reporter group at the 5' end and a fluorescent quencher group at the 3' end, or is connected to a fluorescent reporter group at the 3' end and a fluorescent quencher group at the 5' end.

8. The nucleic acid molecule of claim 7, wherein the fluorescent reporter group is selected from the group consisting of hydroxycoumarin, methoxycoumarin, Alexa fluor, aminocoumarin, Cy2, FAM, Alexa fluor488, Fluorescein FITC, Alexafluor 430, JOE, TET, Alexa fluor 532, HEX, VIC, Cy3, TRITC, Alexa fluor 546, Alexafluor 555, R-phycoerythrin (PE), Rhodamine Red-X, TAMRA, Cy3.5, Rox, Alexa fluor568, Red613, Texas Red, Alexa fluor 594, Alexa fluor 633, Allophycocyanin, Alexafluor 633, Cy5, Alexa fluor 660, Cy5.5, TruRed, Alexa fluor 680, NED, SYBR Green I, and Cy7.

9. The nucleic acid molecule of claim 8, wherein the fluorescent reporter group is selected from the group consisting of FAM, HEX, VIC, TAMRA, ROX, CY5, CY5.5, CY3, JOE, TET, Texas Red, NED and SYBR GreenI.

10. The nucleic acid molecule according to any one of claims 7 to 9, wherein the fluorescence quenching group is selected from Dabcyl, BHQ0, BHQ1, BHQ2, BHQ3, BBQ650, Eclipse and MGB.

11. The nucleic acid molecule according to any one of claims 1 to 10, further comprising a nucleic acid molecule group for detecting an internal reference gene.

12. The nucleic acid molecule according to claim 11, wherein the internal reference gene is GAPDH, and the nucleic acid molecule group comprises a forward primer having a nucleotide sequence as shown in SEQ ID NO: 9, a reverse primer having a nucleotide sequence as shown in SEQ ID NO: 10, and a probe having a nucleotide sequence as shown in SEQ ID NO:

11.

13. A method for detecting and / or quantifying pluripotent stem cells in a sample, the method comprising: detecting the expression of the HES3 gene in the sample, Optionally, the detecting is performed by using a nucleic acid molecule according to any one of claims 1-12.

14. The method of claim 13, wherein the sample is a differentiated cell population derived from pluripotent stem cells, such as human pluripotent stem cells.

15. The method of claim 14, wherein the pluripotent stem cells are selected from embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC).

16. The method according to claim 14, wherein the differentiated cells are selected from the group consisting of pluripotent stem cell-induced mesenchymal stem cells, pluripotent stem cell-induced dopaminergic neural precursor cells, and pluripotent stem cell-induced retinal pigment epithelial cells.

17. The method according to any one of claims 13 to 16, comprising extracting mRNA from the sample and reverse transcribing it into cDNA.

18. The method according to claim 17, wherein the detection of HES3 gene expression is performed by polymerase chain reaction (PCR), such as real-time fluorescence quantitative PCR or digital PCR, and optionally, the reverse transcription and PCR are performed sequentially in separate reaction systems or in a one-step reaction system.

19. The method according to any one of claims 13-18, further comprising detecting the expression of an internal reference gene in the sample.

20. The method according to claim 19, wherein the reference gene is selected from the group consisting of genes encoding ATP5F1, TFRC, YWHAZ, RPLP0, RPLP1, ACTB, RPLP2, HPRT1, B2M, RPS18, TBP, PGK1, PPIA, GAPDH and GUSB, preferably a gene encoding GAPDH.

21. A kit comprising the nucleic acid molecule according to any one of claims 1-12.

22. The kit according to claim 21, further comprising one or more of a nucleic acid extraction reagent, a PCR buffer, a DNA polymerase, a reverse transcriptase, and dNTPs.

23. Use of a reagent for detecting HES3 gene expression for detecting the presence and / or quantifying pluripotent stem cells in a sample.

24. The use according to claim 23, wherein the sample is a differentiated cell population derived from pluripotent stem cells, such as human pluripotent stem cells.

25. The use according to claim 23, wherein the agent comprises the nucleic acid molecule according to any one of claims 1-12.

Citation Information

Cited By

  • Method for detecting pluripotent stem cells by means of HES3 detection

    WO2026041049A1